KPRX Kiora Pharmaceuticals, Inc. Stock Quote

KPRX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.67	Insider Own	0.70%	Shs Outstand	12.66M	Perf Week	13.21%
Market Cap	6.00M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	0.00%	Shs Float	12.40M	Perf Month	16.01%
Income	-16.40M	PEG	-	EPS next Q	-0.24	Inst Own	23.40%	Short Float	1.47%	Perf Quarter	-28.02%
Sales	-	P/S	-	EPS this Y	-0.30%	Inst Trans	0.81%	Short Ratio	0.62	Perf Half Y	-70.20%
Book/sh	0.73	P/B	0.62	EPS next Y	1.20%	ROA	-79.70%	Target Price	7.12	Perf Year	-87.60%
Cash/sh	0.59	P/C	0.76	EPS next 5Y	-	ROE	-131.90%	52W Range	0.35 - 6.43	Perf YTD	-70.20%
Dividend	-	P/FCF	-	EPS past 5Y	39.90%	ROI	-	52W High	-93.00%	Beta	0.81
Dividend %	-	Quick Ratio	5.60	Sales past 5Y	-	Gross Margin	-	52W Low	29.80%	ATR	0.06
Employees	14	Current Ratio	5.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.74	Volatility	15.27% 17.14%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-28.70%	Profit Margin	-	Rel Volume	0.19	Prev Close	0.45
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	294.23K	Price	0.45
Recom	2.00	SMA20	11.52%	SMA50	5.09%	SMA200	-54.04%	Volume	56,416	Change	0.00%

Jul-05-22 06:45AM	Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects Newsfile
Jun-27-22 06:53AM	Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa Newsfile
May-31-22 04:30PM	Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Newsfile +10.00%
Apr-25-22 06:45AM	Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022 Newsfile
Apr-15-22 09:00AM	Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update Newsfile
Mar-21-22 06:45AM	Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th Newsfile
Mar-18-22 12:00PM	Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate Benzinga -7.09%
06:45AM	Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP) Newsfile
Feb-08-22 06:45AM	Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference Newsfile
Feb-01-22 06:45AM	Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board Newsfile
Jan-05-22 07:00AM	Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference Newsfile -7.96%
Dec-15-21 07:00AM	Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors Newsfile -27.02%
Dec-14-21 07:15AM	Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease Newsfile -8.89%
Nov-15-21 07:30AM	Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience